FAVLYXA

• tagApproval134 co-mentions · 66 sources
• drugEfudex73 co-mentions · 72 sources
• drugFLUOROURACIL73 co-mentions · 72 sources
• companyFresenius Kabi USA LLC12 co-mentions · 12 sources
• drugRNS-6012 co-mentions · 12 sources
• tagOncology5 co-mentions · 2 sources
• drugOXALIPLATIN1 co-mentions · 1 sources
• drugEntia1 co-mentions · 1 sources

Trials studying FAVLYXA

• phase2Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)recruitingn=298
• phase2Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinomanot yet recruitingn=40
• phase2A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignanciesactive not recruitingn=332
• phase2Pan Tumor Rollover Studyrecruitingn=1,500
• phase2A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)recruitingn=220
• phase2A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancerrecruitingn=390
• phase3A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinomarecruitingn=900
• phase2Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)recruitingn=454